Method for achieving desired glial growth factor 2 plasma levels
AssigneeAcorda Therapeutics, Inc.
InventorsHaesun Kim, Anthony O. Caggiano
Life of this patent
Estimating the term…
Abstract
The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.
Claims9
A method for promoting Schwann cell remyelination following administration of glial growth factor 2 (GGF2) in a subject with a disease or disorder associated with reduced levels of myelination, said method comprising providing GGF2 in a pharmaceutically acceptable carrier, wherein the GGF2 is administered in an amount that elicits a plasma level of about 0.001 nM to 0.01 nM GGF2, or wherein the GGF2 is administered in an amount of about 500 ng of GGF2 per kg of body weight;
- and administering the GGF2 to the subject.
Dependencies are inferred from the claim text.